LogoThe Venture Canyon
Contact

Commentary

Market or Sector Commentary

Commentary

Akero Therapeutics $AKRO, Efruxifermin trials, and why we think Gilead Sciences may be an acquirer

May 23, 2025

•

10 min read

Akero Therapeutics $AKRO, Efruxifermin trials, and why we think Gilead Sciences may be an acquirer

This will be our only write-up in biotech!

Commentary

Lululemon $LULU Outlook

Dec 23, 2024

•

6 min read

Lululemon $LULU Outlook

A brief update on the view of Lululemon going into 2025

Jeff Amapps
Jeff Amapps

Commentary

My $LWAY Thesis is done

Sep 23, 2024

•

1 min read

My $LWAY Thesis is done

Danone offers to buy Lifeway at $25/share

Jeff Amapps
Jeff Amapps

Commentary

$LWAY beat $ONON miss but maintain

Aug 13, 2024

•

3 min read

$LWAY beat $ONON miss but maintain

Jeff Amapps
Jeff Amapps

Commentary

Eyes On Lulu, $RCAT, VIX Feeds Families Monday

Aug 10, 2024

•

4 min read

Eyes On Lulu, $RCAT, VIX Feeds Families Monday

Jeff Amapps
Jeff Amapps

Commentary

Another $MTCH Activist Campaign, Our $0.02

Jul 16, 2024

•

13 min read

Another $MTCH Activist Campaign, Our $0.02

Starboard Value taps Match Group, what value can they really add?

Jeff Amapps
Jeff Amapps
The Venture Canyon

The Venture Canyon


Home
Contact Us
© 2026 The Venture Canyon.
beehiivPowered by beehiiv